Clinically superior scalp cooling
Hair loss is no longer inevitable
FDA cleared for men and women with solid tumor cancers
Clinically superior scalp cooling
Hair loss is no longer inevitable
FDA cleared for men and women with solid tumor cancers

Dignitana AB produces
The DigniCap Scalp Cooling System to minimize hair loss from chemotherapy.

Click HERE to learn more about DigniCap Delta.

DigniCap is designed to safely provide uniform scalp cooling with high efficiency and acceptable comfort. The system consists of a tightly fitting silicone cap that is connected to a cooling and control unit, as well as an insulating neoprene outer cap to maintain fit and the treatment temperature.

The patented DigniCap system has shown excellent scientific results in clinical studies– 67% of patients had a successful outcome and retained their hair in the pivotal trial which led to FDA clearance in 2015.

For product information, visit dignicap.com

ABOUT DIGNITANA READ MORE

Company Profile

Dignitana is a Swedish medical technology company publicly traded on Nasdaq First North Growth Market. Company headquarters are in Lund, Sweden and operations are based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy.

The company develops, produces and markets The DigniCap® Scalp Cooling System. It is a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and acceptable patient comfort. In 2017, Dignitana received an expanded clearance from the FDA, allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors from breast cancer as well as those from prostate, ovarian, uterine, lungs and other tissues.

ANNOUNCEMENTS

Annual General Meeting 
25 May 2022

Dignitana AB Appoints Nomination Committee
Dignitana, world leader in scalp cooling innovation, has appointed the Nomination Committee for the 2022 Annual General Meeting to be held 25 May 2022.
The Nomination Committee will consist of Greg Dingizian, Chairman of the Board and Owner of Adma Förvaltnings AB on closely related company’s mandate; Bo Lundgren, appointed by Swedbank Robur AB on closely related company mandate; and Klas Arildsson, Chairman of the Board of Dignitana AB.
The nomination committee shall give proposals for chairman at the AGM, election and remuneration of board members and, where applicable, remuneration for work in the board’s committees, election and remuneration of auditors and, where applicable, changes of principles for appointment of nomination committee. Shareholders wishing to make suggestions to the nomination committee may write to investorrelations@dignitana.com by 1 April 2022 at the latest.

FEATURED ANALYSIS

Redeye Research Note
20 March 2021
 
Redeye Research Note
 
Redeye Update

FEATURED VIDEOS

Saving Identity
1 September 2019
In the film “Saving Identity” Dr. Hope Rugo of UCSF explains how scalp cooling reduces hair loss from chemo and the process from gaining approval for the first FDA cleared scalp cooling system in the US in 2015 to the launch of the new DigniCap Delta device in 2019.

MEDIA

Börsveckan
27 January 2020
Dignitana featured analysis in Börsveckan.

Please note that the content of this website is not intended as professional medical or healthcare advice and should not be construed as a substitute for professional healthcare advice, or services from a qualified professional healthcare provider familiar with your unique situation. This content is intended solely as a general product and corporate information.

OPERATIONS
Dignitana
10925 Estate Lane, Suite 185
Dallas, TX 75238
+1 469-917-5555

HEADQUARTERS
Dignitana AB
Traktorgränden 3
226 60 Lund, Sweden
+46 46 16 30 90

HEADQUARTERS
Dignitana S.r.l.
Corso di Porta Nuova, 46
20121 Milan, Italy